The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Emerging immunotherapy biomarkers for predicting systemic therapy in HCC
Mark Yarchoan, MD, Johns Hopkins University, Baltimore, MD, provides an overview of emerging immunotherapy biomarkers for predicting systemic therapy in hepatocellular carcinoma (HCC). He highlights the challenge of lacking an effective biomarker to choose between various regimens for first-line HCC treatment. Dr Yarchoan mentions that multiple biomarkers, such as tumor mutational burden and PD-L1 expression, have been investigated, but none have proven effective in this context. He discusses the controversy surrounding the potential relationship between etiology and immunotherapy response, emphasizing that, based on the available data, etiology should not be a determining factor in selecting first-line systemic regimens for HCC. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
